Objective To evaluate the efficacy and safety of amisulpride in acute exacerbation patients with schizophrenia.Methods In this study,one hundred and forty-four acute episode patients with schizophrenia, qualifyed with the International Classification of Diseases 10th revision, were enrolled. All patients received monotherapy of amisulpride for 8 weeks.The initial dose of amisulpride was 200 mg/d,and the dose was flexible during the 8 weeks according to the investigator judgement based upon symptoms and tolerability.Recommended therapeutic dose was 800 mg/d and maximum dose was 1 200 mg/d.The Positive and Negative Syndrome Scale (PANSS) was applied at the baseline and the 2nd, 4th, 8thweek.The Clinical Global Impression Scale-Severity and Improvement(CGI-S,CGI-I)and the Personal and Social performance Scale(PSP)were adopted at the baseline and endpoint of treatment.The safety was evaluated by the Udvalg for Kliniske Undersogeser Side Effect Rating Scale,laboratory tests and electrocardiogram.The efficacy and safety were analyzed by using perprotocol and safety sets respectively.Results One hundred and thirty two patients completed this trial,and 12 patients dropped out during the study. After 8-week treatment, the positive scores(22.0 ± 6.6 vs.10.0 ± 3.8),negative scores(22.7 ± 7.7 vs.13.9 ± 6.8),general psychopathology scores(41.6 ± 9.0 vs.25.1 ± 7.4)and the total scores(86.5 ± 16.0 vs.49.0 ± 16.0)of PANSS were significantly improved(P<0.01);77.3% patients had symptoms reduced in PANSS total scores by at least 50%,and the result was accordant to significant CGI-I improvement in 75.8% patients. Besides these, the PANSS response rate was significantly higher in positive scores than in negative scores(χ2=9.52,P<0.01).PSP was also significantly improved after 8-week treatment (t=18.10, P<0.01). The most popular side effects were extrapyramidal symptoms(29.2%) and hyperprolactinemia(23.6%). Conclusions Amisulpride is effective in treating psychopathological symptoms of acute exacerbations patients with schizophrenia, the most frequent side effects are seen in extrapyramidal symptoms and hyperprolactinemia.

Objective To evaluate the efficacy and safety of amisulpride in acute exacerbation patients with schizophrenia.Methods In this study,one hundred and forty-four acute episode patients with schizophrenia, qualifyed with the International Classification of Diseases 10th revision, were enrolled. All patients received monotherapy of amisulpride for 8 weeks.The initial dose of amisulpride was 200 mg/d,and the dose was flexible during the 8 weeks according to the investigator judgement based upon symptoms and tolerability.Recommended therapeutic dose was 800 mg/d and maximum dose was 1 200 mg/d.The Positive and Negative Syndrome Scale (PANSS) was applied at the baseline and the 2nd, 4th, 8thweek.The Clinical Global Impression Scale-Severity and Improvement(CGI-S,CGI-I)and the Personal and Social performance Scale(PSP)were adopted at the baseline and endpoint of treatment.The safety was evaluated by the Udvalg for Kliniske Undersogeser Side Effect Rating Scale,laboratory tests and electrocardiogram.The efficacy and safety were analyzed by using perprotocol and safety sets respectively.Results One hundred and thirty two patients completed this trial,and 12 patients dropped out during the study. After 8-week treatment, the positive scores(22.0 ± 6.6 vs.10.0 ± 3.8),negative scores(22.7 ± 7.7 vs.13.9 ± 6.8),general psychopathology scores(41.6 ± 9.0 vs.25.1 ± 7.4)and the total scores(86.5 ± 16.0 vs.49.0 ± 16.0)of PANSS were significantly improved(P<0.01);77.3% patients had symptoms reduced in PANSS total scores by at least 50%,and the result was accordant to significant CGI-I improvement in 75.8% patients. Besides these, the PANSS response rate was significantly higher in positive scores than in negative scores(χ2=9.52,P<0.01).PSP was also significantly improved after 8-week treatment (t=18.10, P<0.01). The most popular side effects were extrapyramidal symptoms(29.2%) and hyperprolactinemia(23.6%). Conclusions Amisulpride is effective in treating psychopathological symptoms of acute exacerbations patients with schizophrenia, the most frequent side effects are seen in extrapyramidal symptoms and hyperprolactinemia.

Objective To discuss the clinical features of behavioral and psychological symptoms of demen-tia(BPSD)and the relation between different sub-clinical syndromes and cognition. Methods One hundred and sixteen dementia patients were assessed with neuropsychiatric inventory and mini-mental state examination (MMSE)and made factor analysis according to DSM-IV-R. Results Twelve common behavioral and psychological symptoms could be further divided into five sub-syndromes,including disinhibition behavior,psychosis,agitation, emotion and apathy factors. MMSE total score and years of education entered regression equation of apathy factor (P<0.05). Conclusion BPSD can be divided into five factors and apathy factor are related with cognitive function.

OBJECTIVEAlpha-2 macroglobulin (alpha2M) is a proteinase inhibitor found in association with senile plaques in Alzheimer's disease (AD). Also alpha2M has been implicated in several pathophysiological processes in AD. In view of the recent contradictory reports on the relationship between AD and a common polymorphism I1000V in A2M gene, the present authors studied a relatively large sample, determined the genotype of the I1000V polymorphism in A2M gene in sporadic AD patients and age-matched controls with normal cognition, and examined the possible association of the polymorphism with AD.

METHODSGenotypes of A2M and apolipoprotein E (apoE) were detected by polymerase chain reaction combined with restriction fragment length polymorphism in 257 patients and 242 controls in Guangzhou, and 112 patients and 113 controls in Chengdu.

RESULTSThe 1000Val allele frequencies in the merged AD and control groups were 7.7% and 8.7%, respectively. The differences of allelic and genotypic frequencies between the patients and control subjects were not statistically significant, even after stratification by apoE epsilon4 status or by age-of-onset of the disease.

CONCLUSIONThe results of this study revealed no association between the I1000V polymorphism of A2M and Chinese sporadic AD in Guangzhou and Chengdu.

Aged ; Aged, 80 and over ; Alzheimer Disease ; ethnology ; genetics ; Apolipoproteins E ; genetics ; Asian Continental Ancestry Group ; genetics ; China ; Female ; Gene Frequency ; Genetic Predisposition to Disease ; Genotype ; Humans ; Male ; Middle Aged ; Polymerase Chain Reaction ; Polymorphism, Genetic ; genetics ; Polymorphism, Restriction Fragment Length ; alpha-Macroglobulins ; genetics